ALT Altimmune, Inc.
Debt Financing ·
Altimmune drew $10.0 million on October 27, 2026, and the draw extended the interest-only period to June 1, 2028 while adding a minimum cash covenant tied to the loan balance.
Altimmune sold 64,250,000 shares at $3.00 with a warrant for each share, against a last reported sale price of $3.47 on April 22, 2026.
Shareholders approved raising authorized common stock from 200,000,000 to 400,000,000 shares, against 130,105,177 shares outstanding at the March 13, 2026 record date.
Altimmune is selling 12,397,920 shares at $4.40 each, plus pre-funded warrants for 4,647,534 shares, to one investor, with Titan Partners Group LLC as sole placement agent.
The amendment raises term loan availability from $100.0 million to $125.0 million and extends the interest-only period to 30 months. Altimmune held $210.8 million in cash, cash equivalents and short-term investments at September 30, 2025.
The term loan has four tranches and matures June 1, 2029. The company reported $150 million in cash, cash equivalents and short-term investments as of March 31, 2025.
Altimmune's $400 million shelf would also carry a $150 million share sales program, with Leerink Partners, Piper Sandler and Stifel as sales agents. The filing itself sells no shares.
Altimmune, Inc. develops pemvidutide, its lead product candidate, which it is studying in three indications. In MASH, the IMPACT Phase 2b trial reported positive 48-week topline results on December 19, 2025, with statistically significant improvements versus placebo across treatment arms in the anti-fibrosis measures ELF and LSM. The company lists the conduct of a Phase 3 clinical trial for pemvidutide in MASH among its planned activities. For AUD, the RECLAIM Phase 2 trial completed enrollment, the FDA granted Fast Track designation, and topline results are expected in 2026. For ALD, the RESTORE Phase 2 trial began enrolling in July 2025 across 34 sites in the United States. The company has not generated revenue from product sales to date, and its earlier revenue came mainly from government and foundation grants and contracts. Its consolidated accounts include Altimmune UK, Ltd, Spitfire Pharma, LLC and Altimmune AU Pty, Ltd.
| Product or program | What it is | Stage |
|---|---|---|
| pemvidutide | Lead product candidate studied in MASH, AUD and ALD | Phase 2b completed in MASH (IMPACT); Phase 2 in AUD and ALD |
| RECLAIM | Phase 2 trial of pemvidutide in AUD | Phase 2; enrollment completed |
| RESTORE | Phase 2 trial of pemvidutide in ALD | Phase 2 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $41,000 | $20,000 |
| Research and development | $66.4 million | $82.2 million |
| Net income (loss) | -$88.1 million | -$95.1 million |
| Cash from operations | -$67.5 million | -$79.8 million |
| Cash and equivalents | $43.8 million | $36.9 million |
| Short-term investments | $229.7 million | $95.0 million |
Our latest story on this, dated Apr 22, 2026: "Altimmune launches stock and warrant offering, later prices it at $3.00". The story links the filing or release it is based on. Read the story.
Altimmune, Inc. trades under the ticker ALT on NASDAQ.
Altimmune, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:ALT1; BMV:ALT1; GETTEX:3G0; LS:A2N5Z6; LSX:A2N5Z6.
The SEC Central Index Key (CIK) for Altimmune, Inc. is 1326190. Its filings are on SEC EDGAR.
194,517,701 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Altimmune, Inc. under United States.
Our directory classifies Altimmune, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Altimmune, Inc. is US02155H2004.
aibio.space lists Altimmune, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Altimmune, Inc. develops pemvidutide, its lead product candidate, which it is studying in three indications. In MASH, the IMPACT Phase 2b trial reported positive 48-week topline results on December 19, 2025, with statistically significant improvements versus placebo across treatment arms in the anti-fibrosis measures ELF and LSM.
pemvidutide: Lead product candidate studied in MASH, AUD and ALD Stage: Phase 2b completed in MASH (IMPACT); Phase 2 in AUD and ALD.
RECLAIM: Phase 2 trial of pemvidutide in AUD Stage: Phase 2; enrollment completed.
$41,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Altimmune, Inc. reported a net loss of $88.1 million for the fiscal year ended Dec 31, 2025, and used $67.5 million of cash in operations, per its annual report to the SEC.
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio